Canada markets open in 5 hours 50 minutes

Arch Biopartners Inc. (ACHFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.7860+0.0360 (+1.31%)
At close: 03:18PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.7500
Open2.7860
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.7860 - 2.7860
52 Week Range0.9790 - 4.1300
Volume850
Avg. Volume3,723
Market Cap173.067M
Beta (5Y Monthly)1.12
PE Ratio (TTM)696.50
EPS (TTM)0.0040
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

    LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications, including moderate to severe cases of COVID-19, regardless of variant typeTORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch Biopartners”, “Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that H

  • GlobeNewswire

    Shares for Interest Debt Settlement

    TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $424,767.07 in interest accrued up to December 31, 2021 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements (the “Notes”). The shares for debt settlement is pending final approval from the TSX Venture Exchange (

  • GlobeNewswire

    Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury

    TORONTO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their collaborators, have published a paper in the journal Science Advances describing the mechanism of action for dipeptidase-1 (DPEP-1) in acute kidney injury (AKI). Dr. Muruve is also the Chief Science Officer of Arch. In this pre-clinical study, scientists demonstrated